Schedule 13G ownership disclosure
MBX Biosciences Inc
Common Stock · CUSIP: 55287L101
Event date: 2025-09-30
- Filing-level shares
- 2,017,394.00
- Percent of class
- 4.5%
- Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.
Shares: 2,017,394.00 · Class: 4.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001903360-25-000005
- Form type
- SCHEDULE 13G/A
- Filer
- MBX Biosciences, Inc.
- CIK
- CIK 1776111
- Filed
- Nov 12, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership